← Back to Search

Low nicotine content vape with tobacco e-liquids for Tobacco Use

N/A

Waitlist Available

Led By Eric M Donny, PhD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial will test if banning regular nicotine cigarettes encourages smokers to switch to less harmful products, or if higher nicotine/flavored alternatives are needed.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of cigarettes purchased

Secondary outcome measures

Amount of E-liquid purchased

Minnesota Nicotine Withdrawal Scale Scores

Perceived Health Risk Scale Scores

+5 more

Other outcome measures

Biomarkers of exposure during Field Assessment - Carbon Monoxide

Biomarkers of exposure during Field Assessment - Cotinine

Product use themes emerging from the qualitative interviews

+1 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Normal nicotine content vape with tobacco e-liquidsExperimental Treatment1 Intervention

Normal nicotine content vape with tobacco e-liquids

Group II: Normal Nicotine Content Vape with all flavor e-liquidsExperimental Treatment1 Intervention

Normal Nicotine Content Vape with all flavor e-liquids

Group III: Low nicotine content vape with tobacco e-liquidsExperimental Treatment1 Intervention

Low nicotine content vape with tobacco e-liquids

Group IV: Low nicotine content vape with all flavor e-liquidsExperimental Treatment1 Intervention

Low nicotine content vape with all flavor e-liquids

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor

1,240 Previous Clinical Trials

1,004,143 Total Patients Enrolled

3 Trials studying Tobacco Use

40,715 Patients Enrolled for Tobacco Use

National Institute on Drug Abuse (NIDA)NIH

2,465 Previous Clinical Trials

2,618,569 Total Patients Enrolled

30 Trials studying Tobacco Use

6,169 Patients Enrolled for Tobacco Use

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,515 Total Patients Enrolled

8 Trials studying Tobacco Use

8,402 Patients Enrolled for Tobacco Use

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is patient involvement in this clinical trial?

"Affirmative. Clinicaltrials.gov states that this research study is currently accepting participants; the trial was initially announced on July 27th 2022 and updated two days later. The project requires 64 individuals to be recruited from one site for participation in their survey."

Answered by AI

Are opportunities still available to participate in this experiment?

"Affirmative. The clinical trial, which was originally published on July 27th 2022 and most recently updated on the 29th of July, is actively recruiting patients. This study requires 64 subjects to be enlisted from a single site."

Answered by AI

Recent research and studies

AddictionJournal

Let Actual Markets Help Assess the Worth of Optional Very-low-nicotine Cigarettes Before Deciding on Mandatory Regulations

Kozlowski, Lynn T.. 2016. “Let Actual Markets Help Assess the Worth of Optional Very-low-nicotine Cigarettes Before Deciding on Mandatory Regulations”. Addiction. Wiley. doi:10.1111/add.13515.

International Journal of Drug PolicyJournal

Prospects for a Nicotine-reduction Strategy in the Cigarette Endgame: Alternative Tobacco Harm Reduction Scenarios

Kozlowski, Lynn T.. 2015. “Prospects for a Nicotine-reduction Strategy in the Cigarette Endgame: Alternative Tobacco Harm Reduction Scenarios”. International Journal of Drug Policy. Elsevier BV. doi:10.1016/j.drugpo.2015.02.001.

formation/NLM/NIH, NCBI. “Gprobe”. 2017. Web. <https://github.com/ncbi/gprobe>..Journal

Gprobe

Information/NLM/NIH, NCBI. 2017. “Gprobe”. GitHub repository. https://github.com/ncbi/gprobe.

Tobacco ControlJournal